p16/MTS1 inactivation in ovarian carcinomas: High frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors

International Journal of Cancer

Volumn 79, Issue 1, 1998, Pages 61-65

  Milde Langosch, Karin ^a   Ocon, Erika ^a   Becker, Gabriele ^a   Löning, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; FEMALE; GENE DELETION; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; TISSUE SECTION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, MUCINOUS; AGED; CARCINOMA; CARCINOMA, ENDOMETRIOID; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYSTADENOCARCINOMA, PAPILLARY; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0032549041     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980220)79:1<61::AID-IJC12>3.0.CO;2-K     Document Type: Article

References (25)

1. CAIRNS, P., MAO, L., MERLO, A., LEE, D.J., SCHWAB, D., EBY, Y. TOKINO, K., VAN DER RIET, P., BLAUGRUND, J.E. and SIDRANSKY, D., Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265, 415-416 (1994).
2. CALDAS, C., HAHN, S.A., DA COSTA, L.T., RSDSTON, M.S., SCHUTTE, M., SEXMOUR, A.B., WEINSTEIN, C.L., HRUBAN, R.H., YEO, C.J. and KERN, S.E., Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature (Genet.) 8, 27-32 (1994).
3. CAMPBELL., I.G., BEYNON, G., DAVIS, M. and ENGLEFIELD, P., LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int. J. Cancer, 63, 222-225 (1995).
4. CUATRECASAS, M., VILLANUEVA, A., MATIAS-GUIU, X. and PRAT, J., K-ras mutations in mucinous ovarian tumors. Cancer, 79, 1581-1586 (1997).
5. DIEBOLD, J., SUCHY, B., BARETTON, G.B., BLASENBREU, S., MEIER, W., SCHMIDT, M., RABES, H. and LÖHRS, U., DNA ploidy and myc DNA amplification in ovarian carcinomas. Correlation with p53 and bel-2 expression, proliferative activity and prognosis. Virchows Arch., 429, 221-227 (1996).
6. GERADTS, J., KRATZKE, R.A., NIEHANS, G.A. and LINCOLN, C.E., Immunohistochemical detection of cyclin-dependent kinase inhibitor 2/multiple lumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival solid tumors: correlation with retinoblastoma protein expression. Cancer Res., 55, 6006-6011 (1995).
7. GONZALES-ZULUETA, M., BENDER, C.M., YANG, A.S., NOLJYEN, T., BEART, R.W., VAN TURNOUT, J.M. and JONES, P.A., Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55, 4531-4535 (1995).
8. HERMAN, J.G., GRAFF, J.R., MYÖHÄNEN, S., NELKIN, B.D. and BAYLIN, S.B., Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. nat. Acad. Sci. (Wash.), 93, 9821-9826 (1996).
9. HERMAN, J.G., MERLO, A., MAO, L., LAPIDUS, R.G., ISSA, J.-P.J., DAVIDSON, N.B., SIDRANSKY, D. and BAYLIN, S.B., Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55, 4525-4530 (1995).
10. HUSSUSSIAN, C.J., STRUEWING, J.P., GOLDSTEIN, A.M., HIGGINS, P.A.T., ALLY, S., SHEAHAN, M.D., CLARK, W.H., JR., TUCKER, M.A. and DRACOPOLI, N.C., Germline p16 mutations in familial melanoma. Nature (Genet.), 8, 15-21 (1994).
11. KAMB, A., GRUIS, N.A., WEAVER-FELDHAUS, J., LIU, Q., HAKSHMAN, K., TAVTIGIAN, S.V., SZOCKERT, E., DAY, R.S., JOHNSON, B.E. and SKOLNICK, M.H., A cell cycle regulator potentially, involved in genesis of many tumor types. Science, 264, 436-440 (1994).
12. KAPPES, S., MILDE-LANGOSCH, K., KRESSIN, P., PASSLACK, B., DOCKHORN-DWORNICZAK, B., RÖHLKE, P. and LÖNING, T., p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophqresis, direct sequencing and immunohistochemistry. Int. J. Cancer, 64, 52-59 (1995).
13. ink4a: a gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression. Oncogene, 12, 2041-2044 (1996).
14. QUELLE, D.E., ZINDY, F., ASHMUN, R.A. and SHERR, C.J., Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83, 993-1000 (1995).
15. RODABAUGH, K.J., BIGGS, R.B., QURESHI, J.A., BARETT, A.J., WELCH, W.R., BELL, D.A., BERKOWITZ, R.S. and MOK, S.C., Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene, 11, 1249-1254 (1995).
16. RÖHLKE, P., MILDE-LANGOSCH, K., WEYLAND, C., PICHLMEIER, U., JONAT, W. and LÖNING, T., p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including Ki67 immunoreactivity. J. Cancer Res. Clin. Oncol. (1997) (In press).
17. SAIGO, P.E., The histopathology of malignant ovarian tumors. In: M. Murkman and W.J. Hoskins (eds.), Cancer of the ovary, pp. 21-46, Raven Press, New York (1993).
18. SCHULTZ, D.C., VANDERVEER, L., BUETOW, K.H., BOENTE, M.P., OZOLS, R.F., HAMILTON, T.C. and GODWIN, A.K., Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res., 55, 2150-2157 (1995).
19. SCHUYER, M., VAN STAVEREN, I.L., KLIJN, J.G., VAN DER BURG, M.E., STOTER, G., HENZEN-LOGMANS, S.C., FOEKENS, J.A. and BERNS, E.M., Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours. Brit. J. Cancer, 74, 1069-1073 (1996).
20. SERRANO, M., HANNON, G.J. and BEACH, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366, 704-707 (1994).
21. SERRANO, M., LEE, H.-W., CHIN, L., CORDON-CARDO, C., BEACH, D. and DEPINHO, R.A., Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37 (1996).
22. INK4A as a human tumor suppressor. Biochim. biophys. Acta, 1242, 165-169 (1996).
23. ink4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res., 57, 2619-2622 (1997).
24. ZHOU, X., TARMIN, L., YIN, Y., JIANG, H.-Y., SUZUKI, H., RHYU, M.-G., ABRAHAM, J.M, and MELTZER, S.J., The MTS1 gene is frequently mutated in primary esophageal tumors. Oncogene, 9, 3737-3741 (1994).
25. ZHUANG, Z., BERTHEAU, P., EMMERT-BUCK, M.R., LIOTTA, L.A., GNARRA, J., LINEMAN, W.M. and LUBENSKY, I.A., A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Amer. J. Pathol., 146, 620-625 (1995).